Connect with us

Hi, what are you looking for?


Soligenix stock rallies 400% on positive HyBryte trial results

soligenix stock rallies on hybryte therapy data

Soligenix Inc (NASDAQ: SGNX) reported positive interim data from a trial of its HyBryte therapy on Tuesday.

HyBryte is the biopharmaceutical firm’s treatment for early-stage cutaneous T-cell lymphoma.

Soligenix stock rallied a whopping 400% following the interim results today.

Here’s why it matters for Soligenix stock

Soligenix has so far enrolled six patients in the aforementioned clinical study. Three of them met the minimum threshold for the treatment to be called a success within eighteen weeks.

The Nasdaq-listed firm is committed to signing up a total of 50 patients eventually to the ongoing trial. Christopher J. Schaber – the chief executive of SNGX said in a press release today:

Following the FLASH study which demonstrated safety and efficacy of shorter courses of HyBryte therapy, we’re pleased to see that continuing treatment for longer time periods is resulting in improved outcomes for patients.

Despite today’s rally, Soligenix stock is still down significantly versus the start of 2024.

SGNX says another patient is showing improvement

Soligenix also confirmed today that two out of the three study participants who are yet to achieve treatment success are in early stages of the therapy only.

The third one, it added, showed significant improvement following eighteen weeks of treatment but is yet to meet the minimum threshold. According to CEO Schaber:

We look forward to working with Dr. Kim on this important study as well as embarking on our confirmatory Phase 3 replication study later this year. We’ll continue to provide additional updates on IIS as data becomes available.

SGNX defines treatment success as 50% or more reduction in the patient’s cumulative mCAILS score versus baseline. Soligenix stock does not currently pay a dividend.

Soligenix topped EPS estimates in fiscal Q1

The massive surge in Soligenix stock on Tuesday is coupled with a huge increase in its trading volume as well.

More than 90 million shares of the biopharmaceutical firm have so far exchanged hands today. In comparison, its daily trading volume sits at less than a quarter-million on average.

In May, SGNX reported 18 cents of per-share loss for its first financial quarter that topped Street estimates by 2 cents. Chief executive Christopher J. Schaber said at the time:

Recently, we completed a public offering with gross proceeds of approximately $4.75 million, which will allow us to continue to move our rare disease pipeline forward.

Soligenix had just over $7.0 million in cash at the end of March, 2024. Dr. Schaber also confirmed in a recent statement that his company is managing cash burn meticulously to hit its near-term milestones.

The post Soligenix stock rallies 400% on positive HyBryte trial results appeared first on Invezz

You May Also Like

Editor's Pick

In Risky Business: Why Insurance Markets Fail and What to Do About It (Yale University Press, 2023), economists Liran Einav (Stanford), Amy Finkelstein (MIT),...

Editor's Pick

If you haven’t been following the “Twitter Files” saga, the gist of it is that the US federal government routinely pressured pre-Musk Twitter, and...

Editor's Pick

On April 23, 1985, the Coca-Cola Company made one of the biggest mistakes in American business history: it changed the formula for Coca-Cola. Outraged...

Editor's Pick

For years the North Korean playbook was obvious to the world. The Democratic People’s Republic of Korea wanted to be the center of attention....

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023